IMF Virtual Regional Community Workshop (RCW) - Mid Atlantic (https://www.myeloma.org/videos/imf-virtual-regional-community-workshop-rcw-mid-atlantic)
Virtual Multiple Myeloma Community Workshop
A virtual multiple myeloma workshop addressing the needs specific to communities in the Mid Atlantic region of the United States.
The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. A member of the IMF Nurse Leadership Board will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.
Myeloma 101 and Frontline Therapy
Joseph Mikhael, MD, M.Ed., FRCPC, FACP reviews multiple myeloma basics including what myeloma is, common symptoms and side effects, advances in how myeloma is initially diagnosed, the stages of myeloma treatment, induction therapy, transplant, and more.
Relapsed Therapy and Clinical Trials
David Vesole, MD, PhD, FACP discusses the types of relapsed disease, what doctors consider when selecting a treatment regimen, relapsed/refractory treatment options, how doctors treat triple and penta-class refractory myeloma, updates on clinical trials, and more.
Managing Multiple Myeloma symptoms and treatment side effects
Kimberly Noonan, DNP, ANP-BC, AOCN (IMF Nurse Leadership Board) discusses how patients can manage myeloma-related symptoms and side effects along with side effects brought on by treatment. She outlines the most common side effects for each myeloma drug category, how to prevent infection, and more.
Additional Resources:
Download the IMF's Multiple Myeloma Informational Booklets:
Download IMF publications (https://www.myeloma.org/cancer-information-series)
What Is a Clinical Trial? (https://www.myeloma.org/clinical-trials)
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax%20CANOVA_M13-494_NCT03539744_a3.pdf)
clinicaltrials.gov Identifier: NCT03539744 - Phase II Relapsed or Refractory Venetoclax Trial (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-338_NCT02899052_a3.pdf)
clinicaltrials.gov Identifier: NCT02899052 - Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-654_NCT03314181_a3.pdf)
clinicaltrials.gov Identifier: NCT03314181
Workshop Sponsors:
